Elevated cholesteryl ester transfer protein (CETP) activity, a major determinant of the atherogenic dyslipidemia, and atherosclerotic cardiovascular disease in South Asians

Aims Why South Asians are at increased risk of premature atherosclerotic cardiovascular diseases compared with other ethnic groups is not fully understood. Atherogenic dyslipoproteinemia – hypertriglyceridemia, elevated numbers of low-density lipoprotein (LDL) particles and low high-density lipoprotein cholesterol (HDL-C) – is more common in South Asians but the mechanisms responsible have not been explicated. Here we examined whether the circulating lipid transfer protein, cholesteryl ester transfer protein (CETP), plays a role in the pathogenesis of the atherogenic dyslipoproteinemia among South Asians. Methods and results CETP activity was determined by exogenous substrate assay in the serum of healthy, metabolically well-characterized individuals of South Asian and European descent (N = 244 and 238, respectively). Serum and lipoprotein lipids and apolipoproteins were measured and lipoprotein particle number and size were quantified via nuclear magnetic resonance spectroscopy. All the elements of the atherogenic dyslipoproteinemia were more severe in South Asians and CETP activity was significantly greater by 30% in South Asians compared with Europeans, adjusted for age, sex, body mass index and waist circumference (p < 0.0001). CETP activity was directly associated with serum triglycerides and inversely with HDL-C in the whole population. CETP activity was also directly related to apoB and LDL particle number. Finally, increased CETP activity was associated with pro-atherogenic reductions in HDL and LDL particle size. Conclusions We identified novel associations between elevated CETP activity and the triad of quantitative and qualitative lipoprotein abnormalities in the atherogenic dyslipidemia in South Asians, a major contributor of increased atherosclerotic cardiovascular diseases in South Asians.

[1]  Salim Yusuf,et al.  Association of risk factors with acute myocardial infarction in Middle Eastern countries: the INTERHEART Middle East study , 2014, European journal of preventive cardiology.

[2]  V. Beral,et al.  Coronary heart disease incidence in women by waist circumference within categories of body mass index , 2013, European journal of preventive cardiology.

[3]  Samia Mora,et al.  High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). , 2012, Journal of the American College of Cardiology.

[4]  R. Collins,et al.  Lipids and Lipoproteins and Risk of Different Vascular Events in the MRC/BHF Heart Protection Study , 2012, Circulation.

[5]  R. Krauss,et al.  Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib[S] , 2012, Journal of Lipid Research.

[6]  A. Goldberg,et al.  Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk , 2012, Diabetes, obesity & metabolism.

[7]  Ming-Dauh Wang,et al.  Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. , 2011, JAMA.

[8]  J. Mckenney,et al.  Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia. , 2011, American heart journal.

[9]  S. Yusuf,et al.  Adipocyte Hypertrophy, Fatty Liver and Metabolic Risk Factors in South Asians: The Molecular Study of Health and Risk in Ethnic Groups (mol-SHARE) , 2011, PloS one.

[10]  JustinaCostandi,et al.  Human Resistin Stimulates Hepatic Overproduction of Atherogenic ApoB-Containing Lipoprotein Particles by Enhancing ApoB Stability and Impairing Intracellular Insulin Signaling , 2011 .

[11]  A. van Tol,et al.  Plasma cholesteryl ester transfer, but not cholesterol esterification, is related to lipoprotein-associated phospholipase A2: possible contribution to an atherogenic lipoprotein profile. , 2011, The Journal of clinical endocrinology and metabolism.

[12]  B. Gersh Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease , 2011 .

[13]  S. Lear,et al.  Ethnic‐Specific Differences in Abdominal Subcutaneous Adipose Tissue Compartments , 2010, Obesity.

[14]  A. Kontush,et al.  Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities , 2010, Current opinion in lipidology.

[15]  G. Lip,et al.  Triglycerides and small dense low density lipoprotein in the discrimination of coronary heart disease risk in South Asian populations. , 2010, Atherosclerosis.

[16]  A. Kontush,et al.  Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors , 2009, European heart journal.

[17]  Tom R. Gaunt,et al.  Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. , 2009, American journal of human genetics.

[18]  N. Burtt,et al.  Association of Blood Lipids With Common DNA Sequence Variants at 19 Genetic Loci in the Multiethnic United States National Health and Nutrition Examination Survey III , 2009, Circulation. Cardiovascular genetics.

[19]  J. Falko,et al.  Dyslipidemia in South Asians living in a western community. , 2009, Journal of clinical lipidology.

[20]  J. Kastelein,et al.  Obesity and dyslipidemia. , 2008, Endocrinology and metabolism clinics of North America.

[21]  H. Soran,et al.  Glycation as an atherogenic modification of LDL , 2008, Current opinion in lipidology.

[22]  Yi Zhang,et al.  Enhanced Cellular Uptake of Remnant High-Density Lipoprotein Particles: A Mechanism for High-Density Lipoprotein Lowering in Insulin Resistance and Hypertriglyceridemia , 2008, Circulation research.

[23]  Martin Adiels,et al.  Overproduction of Very Low–Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[24]  D. Rader,et al.  Is the cholesteryl ester transfer protein proatherogenic or antiatherogenic in humans? , 2007, Journal of the American College of Cardiology.

[25]  M. Deepa,et al.  The metabolic syndrome and dyslipidemia among Asian Indians: a population with high rates of diabetes and premature coronary artery disease. , 2007, Journal of the cardiometabolic syndrome.

[26]  S. Lear,et al.  Visceral adipose tissue accumulation differs according to ethnic background: results of the Multicultural Community Health Assessment Trial (M-CHAT). , 2007, The American journal of clinical nutrition.

[27]  Udo Hoffmann,et al.  Abdominal Visceral and Subcutaneous Adipose Tissue Compartments: Association With Metabolic Risk Factors in the Framingham Heart Study , 2007, Circulation.

[28]  J. Després,et al.  Cardiovascular disease under the influence of excess visceral fat. , 2007, Critical pathways in cardiology.

[29]  D. Rader,et al.  Obesity and atherogenic dyslipidemia. , 2007, Gastroenterology.

[30]  R. Bhopal,et al.  Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overflow hypothesis. , 2007, International journal of epidemiology.

[31]  S. Yusuf,et al.  Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. , 2007, JAMA.

[32]  M. Chapman Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. , 2006, Pharmacology & therapeutics.

[33]  F. Karpe,et al.  Insulin sensitisation affects lipoprotein lipase transport in type 2 diabetes: role of adipose tissue and skeletal muscle in response to rosiglitazone , 2006, Diabetologia.

[34]  S. Verma,et al.  South Asians and cardiovascular risk: what clinicians should know. , 2006, Circulation.

[35]  J. Borén,et al.  Diabetic dyslipidaemia , 2006, Current opinion in lipidology.

[36]  S. Brister,et al.  Is South Asian ethnicity an independent cardiovascular risk factor? , 2006, The Canadian journal of cardiology.

[37]  P. Barter,et al.  Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. , 2006, Journal of the American College of Cardiology.

[38]  P. Barter,et al.  High-density lipoproteins as therapeutic targets , 2005, Current opinion in lipidology.

[39]  Steven Hawken,et al.  Preventive cardiologyAbstractsEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study , 2004 .

[40]  R. Peters,et al.  Plasma Levels of Cholesteryl Ester Transfer Protein and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women: The Prospective EPIC (European Prospective Investigation into Cancer and nutrition)–Norfolk Population Study , 2004, Circulation.

[41]  R. Dullaart,et al.  Alterations in high‐density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins , 2003, European journal of clinical investigation.

[42]  S. Lear,et al.  Modification of the relationship between simple anthropometric indices and risk factors by ethnic background. , 2003, Metabolism: clinical and experimental.

[43]  G. Lewis,et al.  Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. , 2003, Clinical biochemistry.

[44]  D. Rader,et al.  Expression of Human Hepatic Lipase in the Rabbit Model Preferentially Enhances the Clearance of Triglyceride‐Enriched Versus Native High‐Density Lipoprotein Apolipoprotein A‐I , 2003, Circulation.

[45]  D. Rader,et al.  Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[46]  G. Lewis,et al.  Effect of Atorvastatin on High-Density Lipoprotein Apolipoprotein A-I Production and Clearance in the New Zealand White Rabbit , 2002, Circulation.

[47]  S. Kaser,et al.  Relationship Between Cholesteryl Ester Transfer Protein and Atherogenic Lipoprotein Profile in Morbidly Obese Women , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[48]  R. Krauss,et al.  Metabolic origins and clinical significance of LDL heterogeneity DOI 10.1194/jlr.R200004-JLR200 , 2002, Journal of Lipid Research.

[49]  G. Lewis,et al.  Lipolytically Modified Triglyceride-Enriched HDLs Are Rapidly Cleared From the Circulation , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[50]  G. Lewis,et al.  The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. , 2002, Journal of diabetes and its complications.

[51]  S. Yusuf,et al.  Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. , 2001, Circulation.

[52]  A. van Tol,et al.  Proatherogenic Role of Elevated CE Transfer From HDL to VLDL1 and Dense LDL in Type 2 Diabetes: Impact of the Degree of Triglyceridemia , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[53]  S. Yusuf,et al.  Differences in risk factors, atherosclerosis and cardiovascular disease between ethnic groups in Canada: the study of health assessment and risk in ethnic groups (SHARE). , 2000, Indian heart journal.

[54]  A. Tall,et al.  Remodeling of HDL by CETP in vivo and by CETP and hepatic lipase in vitro results in enhanced uptake of HDL CE by cells expressing scavenger receptor B-I. , 1999, Journal of lipid research.

[55]  G. Lewis,et al.  Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. , 1999, The Journal of clinical investigation.

[56]  E. Bruckert,et al.  Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. , 1998, European heart journal.

[57]  C. Mann,et al.  Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. , 1991, The Journal of clinical investigation.